Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Maternal Vascular Malperfusion-Associated Fetal Growth Restriction
NCT07549295Phase 1Enrolling by invitation
- Sponsor
- Xinhua Hospital
- Start
- Jan 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fetal growth restriction (FGR) comparing melatonin group with placebo group (2 arms). Primary endpoints: Intrauterine Fetal Demise and Neonatal Death and Severe Neonatal Complications. Started Jan 2023; status: enrolling by invitation.
02
Drugs
melatonin
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT07549295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549295.